Within the Ras/RTK pathway, epidermal growth factor receptor (EGFR, 30–50% of tumours) and phosphatase and tensin homolog (PTEN, 30%) are the most commonly mutated in GBM, although mutations in NF1 and RAS have also been documented. Here, PTEN is linked to neoplasm.